Compare ARK Genomic Revolution ETF (ARKG) vs Crocs, Inc. (CROX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Crocs, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $41.38, while Crocs, Inc. trades at $133.42 (market cap $6.60B). The key difference: Crocs, Inc. is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | CROX | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $132.78 |
52-Week Low | $23.09 | $73.39 |
Market Cap | — | $6.60B |
Enterprise Value | — | $8.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Crocs (CROX) trades at $132.78, up 4.44% with bullish technical signals and consistent earnings beats. The stock shows strong momentum above key support levels, though profitability metrics declined in 2025 with negative net income margins. Recent partnerships with LEGO and Disney are driving brand innovation and digital engagement.
Outlook remains mixed with analyst consensus favoring Buy (51%) but fundamental headwinds from margin pressure. Key risks include execution on international expansion and debt management. The stock trades near analyst target of $131.75 with upside to $150 if growth initiatives succeed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →
